AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01267981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard diet
Description: After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy.
Study NCT01267981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet + 500 ml of polyethyleneglycol
Description: Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
Study NCT01267981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol
Description: apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
Study NCT02452866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYM-1219
Description: Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
Study NCT02853266 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Archived serum samples are analysed for measurement of biomarker NCRA
Study NCT01412814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy Biomechanical System
Description: The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
Study NCT01412814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Program
Description: Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
Study NCT03380780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
Study NCT03864601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-JNJ-56136379
Description: 14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
Study NCT01120080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Intervention Counseling
Description: The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
Study NCT02091596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PluroGel N
Description: Study Drug
Study NCT02091596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PluroGel
Description: PluroGel Vehicle Placebo Comparator
Study NCT01793480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study NCT03832790 — intervention group
Intervention type: OTHER
Intervention: observation
Description: observation
Study NCT01645891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CDO electrochemical tissue oxygenation system
Description: The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
Study NCT01645891 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Moist Wound Therapy
Description: Moist Wound Therapy in combination with sham or deactivated device
Study NCT02589522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT02589522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02589522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02589522 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo whole-brain radiation therapy
Study NCT04403503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
Study NCT04403503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate, Isobutyl
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
Study NCT02733185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: disodium EDTA
Description: IV Disodium Ethylene diamine tetra acetic acid in 500 cc
Study NCT02733185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Multi Vitamins/Minerals (OMVM)
Description: 6 tablets of Multi-vitamin/Multimineral daily
Study NCT02733185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo disodium EDTA
Description: IV Placebo comparator- 500 normal saline
Study NCT02733185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo disodium EDTA
Description: IV Placebo comparator- 500 normal saline
Study NCT02733185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Multi Vitamins/Minerals (OMVM)
Description: 6 tablets of a placebo Multi-vitamin/Multimineral daily
Study NCT04712019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Incision Negative Pressure Therapy (ciNPT)
Description: Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric at 125mmHg of continuous negative pressure on a closed surgical incision
Study NCT04712019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Silver-containing Dressing
Description: A standard silver-containing dressing applied to a closed surgical incision
Study NCT01943851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
Study NCT06558747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.
Study NCT06558747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
Study NCT03863171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial spin labeling (ASL) magnetic resonance imaging
Description: Arterial spin labeling (ASL) magnetic resonance imaging test
Study NCT03863171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus fluorescein angiography
Description: Fundus fluorescein angiography test
Study NCT03605862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for five days
Study NCT03605862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for five days
Study NCT04448067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Lentil Intake
Description: Dietary intake of moderate or high dose of lentils at midday meals
Study NCT04448067 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Dietary Lentil CONTROL
Description: Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
Study NCT02584998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mailed-FIT
Description: The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
Study NCT02584998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening invitation-reminder
Description: These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
Study NCT02965196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Dexamethasone Therapy
Study NCT02965196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Normal Saline (NaCl 0.9%)
Study NCT03892577 — intervention group
Intervention type: DRUG
Intervention: Precision oncology including targeted therapy and immunotherapy
Description: Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
Study NCT03862794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: new social norm feedback letter with bar chart
Description: letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
Study NCT03862794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard social norm feedback letter
Description: social norm feedback letter used as standard practice, without specific information about the prescribing percentile
Study NCT04069832 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Single-Session Consultation
Description: A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
Study NCT02269410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GBP-SPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
Study NCT02269410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GBP-HPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
Study NCT02269410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSG-SPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
Study NCT02269410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSG-HPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
Study NCT02662764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalviso™ 15 mcg
Description: Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
Study NCT02544425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
Study NCT02544425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
Study NCT02544425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: It will be administered 40mg/day PO or IV D1-3
Study NCT02544425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
Study NCT02544425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6
Study NCT02544425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2
Study NCT03061448 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based cognitive-behavior therapy
Description: Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
Study NCT03061448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavior therapy
Description: Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
Study NCT01291225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Playground renovation and development
Description: Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
Study NCT01291225 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational campaign
Description: Educational materials will be developed and distributed in Ross County.
Study NCT03329521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
Study NCT03340558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
Study NCT03340558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: MEK inhibitor
Study NCT03313258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group
Description: ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
Study NCT02263248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
Study NCT03313258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Warming Group
Description: ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
Study NCT03764423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon fishmeal
Description: Salmon fishmeal with high protein content
Study NCT03764423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
Study NCT01267253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib Alaninate
Description: Given PO
Study NCT01267253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02377960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB model-based initiation of antihypertensive medication
Description: 1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
Study NCT02377960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored SMS-text message support
Description: 2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
Study NCT02377960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT00147225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)
Study NCT00147225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
Study NCT02263248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venlafaxine
Description: slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
Study NCT02263248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
Study NCT02840175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
Study NCT02840175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
Study NCT02840175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
Study NCT02840175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks
Study NCT00147225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 75-90 mg/m\^2 IV
Study NCT00147225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.
Study NCT02263248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.